Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 52,183 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 52,183 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total transaction of $933,553.87. Following the completion of the transaction, the chief financial officer now directly owns 225,571 shares of the company’s stock, valued at approximately $4,035,465.19. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $17.17 on Friday. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44. The company’s fifty day moving average is $15.45 and its two-hundred day moving average is $14.02. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of research analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. JPMorgan Chase & Co. raised their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Finally, Needham & Company LLC raised their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DAWN. China Universal Asset Management Co. Ltd. raised its holdings in shares of Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at $29,000. Quintet Private Bank Europe S.A. raised its position in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after acquiring an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after acquiring an additional 2,554 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.